IP Library Granted Patent US 10,881,632
Granted Patent B2
US 10,881,632 · App. 16/894,567 · Granted Jan 5, 2021

Stable pharmaceutical composition and methods of using same

Inventors: Mehar Manku (Birmingham, GB); Ian Osterloh (Kent, GB); Pierre Wicker (Mystic, CT); Rene Braeckman (Richboro, PA); Paresh Soni (Mystic, CT)
Assignee: Amarin Pharmaceuticals Ireland Limited
A61K31/202A61K9/48A61K9/4825A61K9/4858A61K31/232A61K45/06A61P3/06A61P9/00A61P9/04A61P9/06A61P9/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,881,632
App. No.
16/894,567
Granted
Jan 5, 2021
Kind
B2
Abstract

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.

Claims (9)

1. A method of reducing triglyceride levels in a subject on statin therapy and having atrial fibrillation and triglycerides of greater than 500 mg/dl, the method comprising administering to the subject about 4 g of per day of ethyl eicosapentaenoate.

2. The method of claim 1 , wherein the subject has a baseline LDL-C level of about 40 mg/dL to about 100 mg/dL.

3. The method of claim 1 , wherein the ethyl eicosapentaenoate is present in a pharmaceutical composition and the ethyl eicosapentaenoate comprises at least about 96 wt. % of all omega-3 fatty acids in the pharmaceutical composition.

4. The method of claim 3 , wherein about 1 g of the pharmaceutical composition is present in each of 4 capsules.

5. The method of claim 1 , wherein the subject is administered the ethyl eicosapentaenoate for a period of at least about 2 years.

6. The method of claim 1 , wherein the subject exhibits a reduction in triglyceride levels by at least about 5% after administration of the ethyl eicosapentaenoate.

7. The method of claim 1 , wherein the subject exhibits a reduction in triglyceride levels by at least about 10% after administration of the ethyl eicosapentaenoate.

8. The method of claim 1 , wherein the subject exhibits a reduction in triglyceride levels by at least about 15% after administration of the ethyl eicosapentaenoate.

9. The method of claim 1 , wherein the subject exhibits a reduction in triglyceride levels by at least about 20% after administration of the ethyl eicosapentaenoate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2020
From: MANKU, MEHAR; OSTERLOH, IAN; WICKER, PIERRE; BRAECKMAN, RENE; SONI, PARESH
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 052864/0953 →